Digest Network Come funziona
Network
/
Società
Fr
Non verificato

Fresenius Kabi

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaSaluteSanità

42 comunicati stampa

Guarda tutti i comunicati
06/09/2026
Fresenius Kabi and AABB Announce 21st Annual Blood Collectors Week, September 6–12, 2026, Honoring Lifesaving Blood Collection Professionals
Fonte
Fresenius Kabi
Emittente
Business Wire
1.00
0
03/09/2026
Fresenius Kabi Launches Generic Sugammadex in Simplist® Ready‑to‑Administer Prefilled Syringe in the U.S.
Fonte
Fresenius Kabi
Emittente
Business Wire
1.00
0
10/08/2026
Fresenius Kabi Issues Nationwide Recall of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL Vials Due to Presence of Glass Particles
Fonte
Fresenius Kabi
Emittente
Business Wire
1.00
0
04/08/2026
Fresenius Kabi Issues Voluntary Nationwide Recall of One Lot of Morphine Sulfate Injection, USP in a Simplist® Prefilled Syringe Due to Labeling Mix-up
Fonte
Fresenius Kabi
Emittente
Business Wire
1.00
0
03/08/2026
Industria
Scienza
Igiene alimentare
Medicina - Varie
Biotecnologia
Sanità
Salute
Farmaceutica
Fresenius Announces FDA Approval of Rituximab Biosimilar for the U.S. Market
Fonte
Fresenius Kabi
Emittente
Business Wire
1.00
0
31/07/2026
Industria
Biotecnologia
Igiene alimentare
Sanità
Salute
Farmaceutica
Scienza
Medicina - Varie
Fresenius Announces FDA and EMA Acceptance for Review of Vedolizumab Biosimilar Candidate
Fonte
Fresenius Kabi
Emittente
Business Wire
1.00
0
09/04/2026
Industria
Biotecnologia
Farmaceutica
Sanità
Salute
Igiene alimentare
HIV, AIDS e malattie autoimmuni
CMS Grants Fresenius Kabi COVID-19 Indication-Specific HCPCS Codes for Tyenne® (tocilizumab-aazg)
Fonte
Fresenius Kabi
Emittente
Business Wire
1.00
0
20/01/2026
Fresenius Kabi Recognized as a Top Employer in the United States for the Fourth Consecutive Year
Fonte
Fresenius Kabi
Emittente
Business Wire
1.00
0
14/01/2026
Multimedialità
Industria
Igiene alimentare
Biotecnologia
Salute
Farmaceutica
Sanità
Oncologia
Mercato del lavoro
Fresenius Kabi, TQ Therapeutics Announce Cell Therapy Technology Agreement
Fonte
Fresenius Kabi
Emittente
Business Wire
1.00
0
06/01/2026
Fresenius Kabi Introduces New Presentation of Otulfi® (ustekinumab-aauz), a Biosimilar to Stelara®
Fonte
Fresenius Kabi
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0